R&D Progress: The Path to New Medicines

To deal with the innovation dilemma (patent loss, pipeline drying up), big pharmaceutical corporations use innovative business models to boost R&D and innovation productivity. As a result of these challenges, major corporations have had to alter or reinvent their business models in order to maintain value creation through R&D and innovation. However, to our knowledge, there is still a dearth of understanding about the "strategic alignment" of these organizational changes, as well as how organizational members view them.

Related Societies:

The International Society for Pharmaceutical Engineering (ISPE), The European Federation of Pharmaceutical Industries and Associations (EFPIA), The European Generic Medicines Association (EGA), The European Personalised Medicine Association EPEMED.

 

    Related Conference of R&D Progress: The Path to New Medicines

    April 16-17, 2026

    19th European Biosimilars Congress

    Rome, Italy
    April 27-28, 2026

    9th European Biopharma Congress

    Paris, Aland Islands
    May 28-29, 2026

    3rd International Conference on Pharmacognosy

    Madrid, Spain
    June 08-09, 2026

    20th World Drug Delivery Summit

    London, UK
    July 27-28, 2026

    39th World Congress on Pharmacology

    Rome, Italy
    July 27-28, 2026

    19th World Drug Delivery Summit

    Paris, France
    September 24-25, 2026

    6th World Congress on Rare Diseases & Orphan Drugs

    Paris, France
    November 26-27, 2026

    5th World Congress on Precision and Personalized Medicine

    Zurich, Switzerland
    November 26-27, 2026

    5th World Conference on Pharma Industry and Medical Devices

    Zurich, Switzerland

    R&D Progress: The Path to New Medicines Conference Speakers

      Recommended Sessions

      Related Journals

      Are you interested in